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Colorectal cancera b s t r a c t
MicroRNAs (miRNAs) have recently emerged as regulators of metastasis. We provide insight into the
behavior of miR-221 in colorectal cancer (CRC) metastasis by showing that miR-221 is signiﬁcantly
upregulated in metastatic CRC cell lines and tissues. miR-221 overexpression enhances, whereas
miR-221 depletion reduces CRC cell migration and invasion in vitro and metastasis in vivo. We iden-
tify RECK as a direct target of miR-221, reveal its expression to be inversely correlated with miR-221
in CRC samples and show that its re-introduction reverses miR-221-induced CRC invasiveness. Col-
lectively, miR-221 is an oncogenic miRNA which may regulate CRC migration and invasion through
targeting RECK.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) causes more than 600,000 deaths annu-
ally, with more that 1 million cases diagnosed each year [1]. As for
all cancers, the overwhelming cause of death from CRC is metasta-
sis, a complex series of multiple sequential steps during which pri-
mary cancer cells acquire an invasive phenotype enabling them to
translocate from the primary tumor to a distant organ and form a
secondary tumor [2]. Understanding the molecular mechanisms
underlying CRC metastasis is therefore essential for developing
therapies for CRC patients.
MicroRNAs (miRNAs) are emerging as regulators of metasta-
sis by acting on multiple signaling pathways [3]. miRNAs are a
class of small cellular RNAs that regulate post-transcriptionally
protein-coding genes by pairing with their 30 untranslated re-
gions (UTRs), thereby inhibiting translation or causing target
degradation [4]. Imperfect target binding allows miRNAs to
posttranscriptionally regulate entire sets of genes, making miR-
NAs attractive candidate upstream regulators of metastatic pro-
gression, both as promoters and suppressors [5]. In particular,
CRC invasion and metastasis are stimulated by miR-21 and
miR-103/107 by downregulating tumor suppressors PDCD4,
and DAPK and KLF4, respectively, but inhibited by miR-137and miR-30a by downregulating oncogenes FMNL2 and PIK3CD,
respectively [6–9].
miR-221 has been reported to be deregulated in a variety of tu-
mor types. It is encoded in tandem from a gene cluster on the X
chromosome and has been shown to target critical cancer-related
pathways in various cellular contexts, including CRC. It has been
well studied in its oncogenic role as a suppressor of key cell cycle
inhibitors p27(Kip1) and CDKNC/p57 [10–12]. miR-221 is also
overexpressed in human CRC tissues where it has been shown to
promote cell proliferation in vitro by inhibiting cell cycle inhibitor
CDKN1C/p57 in CRC cells [12,13]. However, its role in metastatic
CRC processes remains unexplored.
Reversion-inducing cysteine-rich protein with Kazal motifs
(RECK) is a tumor suppressor that inhibits matrix metallopro-
teinases (MMPs) 2, 9 and 14 and is involved in breaking
down the extracellular matrix [14,15]. RECK downregulation
has been described in a number of cancers [16–18], and re-
stored expression of RECK decreased tumor angiogenesis, inva-
sion and metastasis in vitro and in vivo [19]. Studies on RECK
regulation may therefore reveal further insights into the mech-
anisms of metastasis.
In this study, we explored the possibility that miR-221 may
be involved in CRC cell invasion and metastasis and partially
elucidated the molecular mechanism underlying its effects. We
showed that miR-221 promoted metastasis in vitro and
in vivo and identiﬁed RECK as a direct and functional target
for miR-221 in cell invasion, thus providing a candidate target
for CRC treatment.
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2.1. Cell lines and clinical specimens
Human CRC cell lines SW480, HCT116, HT29, LoVo and
SW620 were obtained from the Cell Bank of Type Culture Col-
lection (Shanghai, China). All cell lines were maintained in Dul-
becco’s modiﬁed Eagle medium (DMEM) supplemented with
10% fetal bovine serum and antibiotics. Ten matched normal co-
lon tissue, primary CRC and lymph node metastatic samples
were collected directly after surgical resection at Renji Hospital
(Shanghai Jiaotong University School of Medicine, Shanghai, Chi-
na). All samples were immediately frozen in liquid nitrogen and
stored at 80 C until use. Approval for this study was obtained
from the Ethics Review Committee of the Institutional Review
Board of Renji hospital and informed consent was obtained from
each patient.
2.2. Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using Quizol reagent (Qiagen, Valen-
cia, CA). Mature miR-211 and U6 levels were quantiﬁed with
TaqMan miRNA assays (Applied Biosystems, Foster City, CA).
RECK and b-actin mRNA levels were determined by qRT-PCR
using the SYBR Green Master Mix on the HT 7500 System (Ap-
plied Biosystems). The PCR primers for RECK were 50-AGCAACC-
GAGCCCGTATGT-30 and 50-CCGAGTAGGCAGCACACACA-30. The
relative expression levels of each gene were calculated and nor-
malized using the 2DDCt method relative to U6 or b-actin. All
of the reactions were run in triplicate.
2.3. Lentivirus infection and oligonucleotide transfection
Pre-miR-221 and RECK encoding sequences were subcloned
into the pCDH-CMV-MCS-EF1-coGFP constructs (System Biosci-
ences, Mountain View, CA). RECK siRNA sequences were sub-
cloned into the pLKO.1 vector (Addgene, Cambridge, MA).
Lentiviral vectors were prepared in accordance with standard
protocols. SW480 cells were infected with the recombinant len-
tivirus-transducing units plus 8 mg/ml polybrene (Sigma, St
Louis, MO). The miR-221 oligonucleotide inhibitor (anti-miR-
221) and its negative control (anti-miR-ctrl) were synthesized
by RiBoBio (Guangzhou, China). SW620 cells were transfected
with oligonucleotides using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol. Cells
were collected 48 h after transfection.
2.4. Vector construction and luciferase reporter assay
The full-length RECK 30UTR was ampliﬁed from normal hu-
man cDNA and cloned into the NotI/XhoI sites downstream of
the stop codon of Renilla luciferase in the pGL-control vector
(Promega, Madison, WI). The corresponding mutant constructs
were created by mutating the seed regions of the miR-221-bind-
ing sites. For the luciferase reporter assay, stably miR-221 or
miR-ctrl expressing HEK293T or SW480 cells were co-transfec-
ted with 200 ng of wild-type 30 UTR or mut 30 UTR and 10 ng
pRL-SV40 Renilla luciferase construct. After 48 h, the cells were
harvested and luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega). The Renilla lucifer-
ase activities were used as an internal control. The experiments
were performed independently in triplicate.2.5. Wound healing and invasion assays
Artiﬁcial wounds were created by using a sterile 200 ll tip to
scrape SW480 and SW620 monolayers that had been serum
starved for 24 h after reaching near conﬂuence in 6-well plates.
Cells were washed with serum-free medium to remove ﬂoating
cells and debris. Representative images (40) of cells migrating
into the wounds were captured at 0 h and 48 h using an inverted
microscope. Cell invasion was determined using 24-well transwell
chambers coated with Matrigel (BD Biosciences, Bedford, MD).
Cells (1.0  105) in serum-free medium were placed into the upper
chamber. The chambers were then inserted into the wells of a plate
incubated for 24 h in DMEM with 10% fetal bovine serum. Cells
which had invaded to the lower surface were ﬁxed, stained and
counted using an inverted microscope (100). All experiments
were performed in triplicate.
2.6. Western blotting
Cells were lysed with RIPA lysis buffer containing protease
inhibitor. Proteins were separated by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis, and transferred to polyvinylidene
diﬂuoride membranes (Millipore, Bedford, MA). Blots were blocked
and then probed with antibodies against RECK (Cell Signaling Tech-
nology, Beverly, MA) and b-actin (Santa Cruz Biotechnology, Santa
Cruz, CA). After washing, the blots were incubated with horserad-
ish peroxidase-conjugated secondary antibodies and visualized
using super enhanced chemiluminescence detection reagent
(Amersham Biosciences, Piscataway, NJ).
2.7. In vivo models
All mouse experiments were conducted with approval from
Shanghai Jiaotong University Animal Care Committee. SW480/
miR-221 or SW620/anti-miR-221 cells were resuspended
(1  106 cells/0.1 ml PBS) and injected into the tail vain of 6-week
old BALB/c nude mice (six in each group). The mice were housed
and maintained under speciﬁc pathogen-free conditions. Liver
metastasis was examined 8 weeks after implantation.
2.8. Statistical analysis
Data were expressed as the mean ± S.D. from at least 3 indepen-
dent experiments. The difference between groups was analyzed
using Student’s t-test when comparing only two groups or one-
way analysis of variance when comparing more than two groups.
The association between miR-221 and RECK expression was evalu-
ated using Spearman’s correlation analysis. P values <0.05 were
considered to be signiﬁcant.
3. Results
3.1. miR-221 is upregulated in metastatic CRC cell lines and clinical
specimens
To probe miR-221’s involvement in CRC metastasis, we mea-
sured miR-221 transcript levels in a panel of CRC cell lines of differ-
ent metastatic potential. qRT-PCR analysis showed that miR-221
levels were higher in metastatic CRC cells (SW620 and LoVo) than
in nonmetastatic ones (SW480, HCT116 and HT29) (Fig. 1A). We
then explored the clinical relevance of this ﬁnding by comparing
miR-221 expression in normal colon tissues with primary CRC
Fig. 1. Increased miR-221 expression in metastatic CRC cell lines and clinical
specimens. (A) qRT-PCR analysis of miR-221 expression in CRC cell lines. (B) qRT-
PCR analysis of miR-221 expression in normal colon tissues, primary CRC tissues
and lymph node metastatic tissues from 10 patients. Data is presented as the
mean ± S.D.; P values were calculated using one-way analysis of variance. ⁄⁄P < 0.01.
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ies [12,13], miR-221 expression was signiﬁcantly higher in primary
CRC tissues compared to normal colon tissues. We extended our
investigations to lymph node metastatic tissues and found that
its miR-221 expression was in turn signiﬁcantly higher than that
of primary CRC tissues (Fig. 1B). These ﬁndings suggest that upreg-
ulation of miR-221 might play a role in CRC metastasis.
3.2. miR-221 modulates CRC cell migration and invasion in vitro
Given its increased expression in metastatic CRC cells, we next
investigated whether miR-221 could regulate CRC cell migration
and invasion in vitro. To do this, we ﬁrst established miR-221 sta-
bly expressing SW480 cells by lentivirus infection. The wound
healing assay demonstrated that miR-221 overexpression signiﬁ-
cantly increased the mobility of SW480 cells (Fig. 2A). Conversely,
knockdown of miR-221 in SW620 cells decreased wound healing
(Fig. 2B). Similarly, in the transwell invasion assay, the invasion
ability of SW480 cells increased upon miR-221 overexpression
but the invasion ability of SW620 cells decreased upon miR-221
knockdown (Fig. 2C and D). These observations suggest that miR-
221 signiﬁcantly promotes in vitro migration and invasion of CRC
cells.
3.3. miR-221 promotes liver metastasis in vivo
To further explore the role of miR-221 on tumor metastasis
in vivo, SW480 cells stably expressing miR-221 were trans-
planted into nude mice through the lateral tail vein. At 8 weeks
after implantation, we found that miR-221 overexpression sig-
niﬁcantly increased the number of metastatic nodules in theliver, while miR-221 knockdown decreased the number of liver
metastases in mice treated with SW620 injection (Fig. 3A and
B). These ﬁndings add further evidence to miR-221’s role as a
metastasis promoter in CRC.3.4. RECK is a direct target of miR-221
To characterize the mechanism by which miR-221 promotes
tumor metastasis, we searched for potential target genes of
miR-221 using two publicly available databases, TargetScan
and miRanda. We were particularly interested in MMP inhibitor
and tumor suppressor RECK because in addition to its anti-inva-
sive properties [15], its mRNA and protein expression are nega-
tively correlated with survival in colorectal cancer [20]. Our
analysis of the 30 UTR sequence of RECK identiﬁed a possible
binding site for miR-221 (Fig. 4A). To test the function of this
potential binding site, we inserted wild-type or mutant 30 UTR
sequences immediately downstream of the luciferase reporter
gene and co-expressed these with either miR-221 or miR-ctrl
in both HEK293 and SW480 cells. As shown in Fig. 4B, miR-
221 overexpression caused a clear decrease in relative luciferase
activity, whereas activity did not drop at all in the mutant 30
UTR reporter, indicating that functionality depends on the intact
seed sequence. Furthermore, qRT-PCR and western blotting anal-
yses showed that miR-221 overexpression signiﬁcantly reduced
the levels of RECK mRNA and protein in SW480 cells, while
miR-221 knockdown increased RECK levels (Fig. 4C and D). To-
gether, these results strongly support a direct suppression of
RECK by miR-221 by means of mRNA degradation as well as
translational repression.
3.5. RECK mediates miR-221-induced invasiveness in CRC cells
To explore the interaction between miR-221 and RECK during
metastasis, we performed gain-of-function and loss-of-function
studies. As has been shown previously for RECK expression in
transformed NIH/3T3ﬁbroblasts [15], ectopic RECK expression
in metastatic CRC cell line SW620 reduced its invasive behavior
(Fig. 5A). Conversely, a reduction of RECK protein levels, either
by siRNA inhibition (Fig. 5B) or miR-221 expression (Fig. 5C) in-
creased CRC cell line SW480 invasiveness. However, cell inva-
siveness returned to control levels when RECK is replenished
(Fig. 5C), suggesting that miR-221 induced invasiveness by
inhibiting tumor suppressor RECK.
3.6. Inverse correlation between miR-221 and RECK in CRC tissues
Finally, we measured the levels of RECK mRNA in primary
CRC and matched lymph node metastatic tissues from CRC pa-
tients. As shown in Fig. 6A, RECK levels were lower in meta-
static tissues than in primary CRC tissues. We then correlated
RECK with miR-221 expression in the same CRC specimens. A
statistically signiﬁcant inverse correlation was observed between
mRNA levels of RECK and miR-221 (R = 0.875, P < 0.001). This
provides further evidence of a potential suppression of RECK
protein levels by miR-221 in metastatic CRC tissues.
4. Discussion
It is becoming increasingly evident that miRNA deregulation
contributes to invasion and metastasis [21,22]. Speciﬁcally for
CRC, it is already known that miRNAs regulate diverse cellular
behaviors controlling invasion and metastasis. Known oncogenic
miRNA targets operate at the levels of transcription (miR-103/
107 target KLF4), translation (miR-21 target PDCD4) and cell
Fig. 2. miR-221 modulates CRC cell migration and invasion in vitro. (A) Wound healing assays were performed in SW480 cells stably expressing miR-221 or the control (miR-
ctrl) (B) Wound healing assays were performed in SW620 cells transiently transfected with anti-miR-ctrl or anti-miR-221. (C) Transwell invasion assays showing the invasion
ability of SW480 cells stably expressing miR-221 or miR-ctrl. (D) Transwell invasion assays showing the invasion ability of SW620 cells transiently transfected with
anti-miR-221 or anti-miR-ctrl. Data is presented as the mean ± S.D.; P values were calculated using Student’s t-test. ⁄⁄P < 0.01.
Fig. 3. miR-221 promotes tumor metastasis in vivo. SW480/miR-221 or SW620/anti-miR-221 cells were intravenously injected into nude mice (n = 6). The formation of liver
metastases was assessed after 8 weeks. (A) Representative photos of metastases in livers from injected mice. The nodules in liver are indicated by arrows. (B) The number of
metastatic nodules in liver per mouse. Data is presented as the mean ± S.D.; ⁄P < 0.05.
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pressor miRNA targets operate at the levels of cell adhesion
and motility (miR-137 target FMNL2) and cell signaling (miR-
30a target PIK3CD and miR-139 target IGF-1R) [8,9,23]. This
study adds miR-221 to the growing group of CRC metastasis-
promoting miRNAs and provides evidence for its targeting of
MMP inhibitor RECK to promote cell invasion.
miR-221 expression is upregulated in CRC, but prior to this study,
apart from its ability to suppress cell proliferation inhibitor
CDKN1C/p57 in vitro, the functional relevance of its upregulation
in CRC was largely unexplored [12,13]. miR-221 has been
extensively studied for its role in regulating key cell cycle inhibitorsp27(Kip1) and CDKNC/p57 and is upregulated in a variety of tumors,
including hepatocellular carcinoma, bladder cancer and pancreatic
cancer [10–12,24–26]. Its invasionpromotingeffects have beendoc-
umented for various cancers, including breast cancer and glioma
[27,28]. In this study we conﬁrm previous reports that miR-221 is
also upregulated in CRC samples and reveal even higher expression
levels in metastatic CRC specimens [12,13]. This expression trend is
also apparent in the cell line SW620, the metastatic derivative
SW480, implying an association between CRC metastasis and in-
creased miR-221 levels. Indeed, Sun and co-workers already ob-
served that miR-221 expression in CRC tumors is higher in
advanced TNM stages III and IV and in tumors invading adjacent
Fig. 4. RECK is a direct target of miR-221 in CRC cells. (A) Diagram of miR-221 sequence matching the seed region in the RECK 30 UTR and the mutation-bearing construct. (B)
Relative luciferase activity in miR-221 or miR-ctrl expressing HEK293T and SW480 cells co-transfected with a wild-type or mutant RECK 30 UTR luciferase reporter construct.
(C) RECK mRNA levels were quantiﬁed by qRT-PCR. (D) RECKprotein levels were quantiﬁed by western blotting. Data is presented as the mean ± S.D.; ⁄⁄P < 0.01.
Fig. 5. Repression of RECK mediates miR-221-induced invasiveness in CRC cells. (A) Western blotting analysis and invasion assays of SW620 cells stably expressing RECK or
vector control. (B) Western blotting analysis and invasion assays of SW480 cells infected with RECK siRNA or its negative control (NC). (C) Western blotting analysis and
invasion assays of SW480 cells stably expressing the control vector, miR-221 or stably expressing miR-221 and RECK.
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sequently showed that ectopic miR-221 expression signiﬁcantly
promoted CRC cell invasion andmetastasis in vitro and in vivo. Con-
versely, knockdown of miR-221 reduced cell invasiveness. Interest-
ingly, thepassenger strandofmiR-221 (miR-221⁄)wasdownregulated
as opposed to upregulated in CRC and its overexpression suppressed
CRC growth and metastasis in mice [29]. Because miR-221 and its
passenger strand are transcribed as one entity, a downregulation of
miR-221⁄ in CRC might reﬂect a post-transcriptional event speciﬁc
to the passenger strand’s nucleotide sequence.
To understand the biological role of miR-221 in CRC invasive-
ness and metastasis, we searched for relevant downstream targets.
In a number of cancers, miRNAs regulate cell invasion by targeting
MMP suppressor RECK [30–32]. It has been previously reported
that RECK expression is low in CRC and is a prognostic marker
of low survival in CRC [20]. In this study, we extend theseobservations to show that RECK expression in malignant CRC cell
line SW620 suppresses invasive activity, as has been shown previ-
ously in transformed NIH/3T3 ﬁbroblasts [15]. We demonstrated
direct binding of miR-221 to the RECK 30 UTR and showed that
miR-221 overexpression diminished but miR-221 knockdown in-
creased RECK mRNA and protein levels in CRC cells. We next estab-
lished a functional connection between miR-221 and RECK in CRC
metastasis by showing that ectopically expressed miR-221’s ability
to induce invasiveness is compromised by ectopic RECK expres-
sion, indicating that RECK suppression is required for miR-221’s
invasive effects. The inverse correlation of miR-221 expression
and RECK protein expression in primary CRC tumors provides fur-
ther evidence for miR-221’s function in metastasis as an inhibitor
of tumor suppressor RECK.
To our knowledge, the present study identiﬁes for the ﬁrst time
RECK as a target of miR-221 and demonstrates that miR-221
Fig. 6. Inverse correlation between miR-221 and RECK in CRC tissues. (A)
Expression of RECK in primary CRC and its matched lymph node metastatic tissues
by qRT-PCR (n = 10). (B) Inverse correlation between miR-221 and RECK in CRC
tissues determined by Spearman’s correlation analysis (R = 0.875, P < 0.001).
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As an MMP inhibitor, RECK is implicated in the control of tissue
degradation and invasive growth, processes central to the epithe-
lial-mesenchymal transition in tumor progression. This work adds
miR-221 to the growing group of CRC metastasis-promoting miR-
NAs and provides insight into the molecular mechanisms of its
metastatic function. Targeting the miR-221 interaction with RECK
would be a helpful therapeutic approach to blocking CRC
metastasis.
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